Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia
Author:
- 5 December 2014
- journal article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2014 (1) , 8-13
Abstract
Characterizing “fitness” in the context of therapeutic decisions for older adults with acute myeloid leukemia (AML) is challenging. Available evidence is strongest in identifying those older adults who are frail at the time of diagnosis by characterizing performance status and comorbidity burden. However, many older adults with adequate performance status and absence of major comorbidity are “vulnerable” and may experience clinical and functional decline when stressed with intensive therapies. More refined assessments are needed to differentiate between fit and vulnerable older adults regardless of chronologic age. Geriatric assessment has been shown to add information to routine oncology assessment and improve risk stratification for older adults with AML. This review highlights available evidence for assessment of “fitness” among older adults diagnosed with AML and discusses future treatment and research implications.Keywords
This publication has 43 references indexed in Scilit:
- Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classificationHaematologica, 2013
- Survival and cure of acute myeloid leukaemia in England, 1971‐2006: a population–based studyBritish Journal of Haematology, 2013
- Outcome of older patients with acute myeloid leukemiaCancer, 2013
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2012
- Survival for older patients with acute myeloid leukemia: a population-based studyHaematologica, 2012
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studyThe Lancet, 2012
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryBlood, 2009
- Age and acute myeloid leukemiaBlood, 2006
- Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:Cancer, 2006
- On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.Journal of Clinical Oncology, 1989